References
Atwal, J.K. et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Trans. Med. 3, 84ra43 (2011)
Yu, Y.J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Trans. Med. 3, 84ra44 (2011)
Yamakawa, H. et al. β-secretase inhibitor potency is decreased by aberrant beta-cleavage location of the “Swedish mutant” amyloid precursor protein. J. Biol. Chem. 285, 1634–1642 (2010).
DeMattos, R.B. et al. Peripheral anti-Aβ antibody alters CNS and plasma clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855 (2001).
Vassar, R. et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).
De Strooper, B., Vassar, R. & Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99–107 (2010).
Eli, Lilly . Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase 3 clinical trials. <http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794> (2010).
Rinne, J.O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363–372 (2010).
Alzheimer Research Forum. Uppsala: Is tau immunotherapy taking off? <http://www.alzforum.org/new/detail.asp?id=2824> (2011).
Kim, S.H. et al. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloidβ42 from isolated intact nerve terminals. J. Neurosci. 30, 3870–3875 (2010).
Yoshimizu, T. & Chaki, S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem. Biophys. Res. Commun. 315, 493–496 (2004).
Ethics declarations
Competing interests
S.G. is a grantee from Amicus Pharmaceuticals and a data and safety monitoring board member of Pfizer/Johnson&Johnson Alzheimer Immunotherapy Alliance.
Rights and permissions
About this article
Cite this article
Alzheimer's therapy: a BACE in the hand?. Nat Med 17, 932–933 (2011). https://doi.org/10.1038/nm0811-932
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0811-932
- Springer Nature America, Inc.
This article is cited by
-
Animal models and conserved processes
Theoretical Biology and Medical Modelling (2012)